• Ícone cinza LinkedIn
  • Instagram
  • Twitter
  • YouTube
 

ABOUT

Vyro is a biotechnology company focused on developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target pediatric and adult brain cancer.

TECHNOLOGY

Vyro proprietary OV technology harness the power from some viruses to infect and selectively and safely kill brain tumor cells. Our results are far superior than conventional treatment.

 
ONCOLYTIC VIRAL IMMUNOTHERAPY (2).png

PIPELINE

Development Stage: Drug discovery & Preclinical

 
 

VYRO TEAM

mayana.jpg

MAYANA ZATZ

Scientific Advisor & Co-founder

Full Professor at University of São Paulo (USP) and Director of The Human Genome and Stem Cell Research Center (HUG-CELL) at USP. Professor Zatz's accomplishments have been recognized and she has received many awards and prizes, including the 2000 L'Oréal-UNESCO Awards for Women in Science.

hugo_edited.jpg

HUGO CABRERA

CEO & Co-founder

Graduated in Business Administration with a Postgraduate Degree in Strategic Business Management at Harvard University. He coordinated the technology transfer from UNIFESP to a private company and participated in the launch of the product to the market in February 2021. In 2020, he led the approval of Phase 1 clinical trial, first-in-human (FIH), by ANVISA to test an ATMP for the treatment of patients in severe COVID-19 condition.

1595373933456_edited.jpg

LUIZ CAIRES

Scientific Advisor & Co-founder

Research scientist and entrepreneur, MBA in Business Management (USP / Esalq), FEA Angels – Associated. He is one of the founding scientists of the line of research and development of medical technologies with Zika virus at the HUG-CELL, which started in 2015, and the study of the oncolytic effects of the Zika virus on CNS tumors.

keith_edited.jpg

OSWALDO KEITH

Scientific Advisor & Co-founder

Associate Professor at the University of São Paulo (USP) and Principal Researcher at The Human Genome and Stem Cell Research Center (HUG-CELL) at USP, where he directs the Translational Genomics Laboratory (LTG) since 2010. Using a multidisciplinary approach, his research laboratory has contributed to a better understanding of the molecular mechanisms that regulate stem cell self-renewal, differentiation, and contribution to the development of cancer.

kaid_edited.jpg

CAROLINI KAID

CSO & Co-founder

Completing 10 years of research experience in the field of cancer biology and genetics. Graduated in Biological Sciences from the University of São Paulo (2012). The first author of the two breakthrough publications on preclinical studies with the oncolytic Zika virus, she is currently continuing to investigate alternative immunotherapies focusing on oncolytic viruses.

ernesto.jpeg

ERNESTO GOULART

Scientific Advisor & Co-founder

Research scientist and entrepreneur with 13 years of experience in biotechnology research. He was the first co-author of pioneering works describing (i) the pathological molecular mechanism of ZIKV and the influence of host genetics on the pathogenesis of congenital ZIKV syndrome, and (ii) the oncolytic potential of ZIKV in the treatment of CNS embryonic tumors.

Design sem nome (2).png